March 6, 2023

NATCO PHARMA (CANADA) INC. ANNOUNCES THE LAUNCH OF PRNAT-POMALIDOMIDE CAPSULES, THE FIRST GENERIC ALTERNATIVE TO POMALYST® IN CANADA

Natco Pharma (Canada) Inc., a subsidiary of Natco Pharma Limited, announced today the launch of PrNAT-POMALIDOMIDE Capsules, the first generic alternative to POMALYST® to be approved by Health Canada.

PrNAT-POMALIDOMIDE is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen that included Lenalidomide. It is also used in combination with Dexamethasone for patients with multiple myeloma for whom both Bortezomib and Lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen.

Read more here